Fortis Healthcare Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemEmphasis Of MatterRelated Party TransactionsResults View source PDF Explain this filing

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.2%Reaction day

₹919.00

prior close

₹916.70

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%-0.6% vs market

Hospital peers, median of 23sector+0.4%-0.6% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.6 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.3

10m

-0.2

15m

+0.3

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.2+0.4-0.6+0.4-0.6

Next day

-1.6+0.7-2.3+1.5-3.1

-0.5+1.3-1.8+1.6-2.1

-1.3-0.3-1.0+1.1-2.4

-0.3+0.2-0.5+0.9-1.2

-0.2-0.0-0.2+1.5-1.7

+1.5+0.3+1.2+0.7+0.8

15d

-3.7-3.7-0.0-3.0-0.7

-12.3-7.9-4.4-6.2-6.1

-5.3-0.5-4.8+1.2-6.4

+4.6+1.5+3.1+6.4-1.8

UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 23Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Fortis Healthcare reported standalone revenue from operations of Rs 442.9 crore for Q3 FY26, up 20.7% from Rs 366.9 crore in Q3 FY25. For the 9-month period, revenue grew 25.9% to Rs 1,331.8 crore versus Rs 1,057.4 crore a year ago. Net profit for Q3 stood at Rs 28.4 crore, down from Rs 39.6 crore in the year-ago quarter, while 9M net profit more than doubled to Rs 205.4 crore from Rs 106 crore, boosted by a Rs 43.2 crore exceptional gain (mainly reversal of subsidiary impairment). EBITDA for 9M was Rs 435.4 crore, up 21.6% YoY, with operating margin expanding to 21.5% from 17.5%. The board also approved a new ESOP 2026 scheme with a pool of 1.5 crore options and revised the Related Party Transaction Policy.

Likely market impact

The strong 9M revenue and earnings growth, along with margin expansion, is a positive signal for shareholders, though Q3 profit dipped due to higher finance costs and lower other income. The long-pending IHH open offer concluded in November 2025, and ESOP 2026 may cause future dilution. The auditor's report is unmodified but draws attention to ongoing SFIO and Supreme Court-related matters, which remain key overhangs to monitor.